People: Valeant Pharmaceuticals International Inc (VRX.N)

VRX.N on New York Stock Exchange

223.02USD
1 May 2015
Change (% chg)

$6.09 (+2.81%)
Prev Close
$216.93
Open
$218.49
Day's High
$223.37
Day's Low
$217.61
Volume
348,460
Avg. Vol
364,537
52-wk High
$227.66
52-wk Low
$106.03

Search Stocks

Summary

Name Age Since Current Position

J. Pearson

55 2011 Chairman of the Board, Chief Executive Officer

Howard Schiller

53 2012 Chief Financial Officer, Executive Vice President, Director

Pavel Mirovsky

64 2013 President and General Manager, Europe

Robert Chai-Onn

44 2015 Executive Vice President, General Counsel and Chief Legal Officer, Head of Corporate and Business Development, Director

Ari Kellen

51 2014 Executive Vice President, Company Group Chairman

Laizer Kornwasser

44 2013 Executive Vice President, Company Group Chairman

Brian Stolz

39 2011 Executive Vice President - Administration, Chief Human Capital Officer

Robert Ingram

72 2011 Lead Independent Director

Ronald Farmer

64 2011 Independent Director

Colleen Goggins

60 Independent Director

Anders Lonner

68 2014 Independent Director

Theo Melas-Kyriazi

55 2010 Independent Director

Robert Power

58 2008 Independent Director

Norma Provencio

57 2010 Independent Director

Katharine Stevenson

52 2010 Independent Director

Jeffrey Ubben

54 2014 Independent Director

Laurie Little

Senior Vice President, Investor Relations

Biographies

Name Description

J. Pearson

Mr. J. Michael Pearson is Chairman of the Board, Chief Executive Officer of Valeant Pharmaceuticals International Inc. Mr. Pearson has been the CEO of the Company and serving on the Board since September 2010 and the Chairman of the Board since March 2011. From February 2008 to September 2010, he was the chairman of the board and CEO of VPI before the Merger. Prior to that, Mr. Pearson served on McKinsey’s board of directors until he left to join VPI. He joined McKinsey in 1984, and over a 23-year career, he worked with leading CEOs and was an integral driver of major turnarounds, acquisitions, and corporate strategy. Within McKinsey, Mr. Pearson held various positions, including head of its global pharmaceutical practice and head of its mid-Atlantic region.

Howard Schiller

Mr. Howard Bradley Schiller is Chief Financial Officer, Executive Vice President, Director of Valeant Pharmaceuticals International Inc. Mr. Schiller has been the Chief Financial Officer (“CFO”) of the Company since December 2011 and has been serving on the Board of the Company since September 2012. Mr. Schiller joined the Company following a 24-year career at Goldman Sachs, a global investment banking firm. From 2009 to 2010, Mr. Schiller was the chief operating officer for the Investment Banking Division of Goldman Sachs, responsible for the management and strategy of the business. From 2003 to 2009, he was responsible for the global healthcare, consumer products, retail, industrial and natural resource businesses in the Investment Banking Division of Goldman Sachs. During his 24 years at Goldman Sachs, he advised large multinational companies on strategic transactions, financings, restructuring and leveraged buyouts.

Pavel Mirovsky

Dr. Pavel Mirovsky is a President and General Manager, Europe of Valeant Pharmaceuticals International, Inc. He was appointed to Valeant’s Executive Management Team in April 2013 and is the President and General Manager, Europe. A medical doctor by training, he has had a distinguished business career. Dr. Mirovsky joined the Company in March 2011 upon the acquisition of PharmaSwiss. Prior to joining PharmaSwiss, Dr. Mirovsky served as regional General Manager at IMS for Central & Eastern Europe, Near East/ Middle East, North Africa, Benelux, Nordics and Portugal. Prior to IMS, he was President and CEO of Polpharma and also led Aventis’ operations in MENA and CEE in senior regional operational roles including Poland and the Baltics. Dr. Mirovsky began his career in the pharmaceutical industry at Rhone Poulenc Rorer, Czech Republic. He worked as an expert for the World Health Organization in Africa, as a visiting scientist at Harvard Medical School and as an assistant professor at University d’Oran in Algeria.

Robert Chai-Onn

Mr. Robert Roswell Chai-Onn is Executive Vice President, General Counsel and Chief Legal Officer, Head of Corporate and Business Development, Director of Valeant Pharmaceuticals International Inc. since January 10, 2014. From March 2012 to January 10, 2014, he was our Executive Vice President, General Counsel and Corporate Secretary, and Corporate Business Development and from September 2010 to March 2012, he was our Executive Vice President, General Counsel and Corporate Secretary. From 2004 to September 2010, Mr. Chai-Onn was Vice President, Assistant General Counsel at VPI. Prior to 2004, Mr. Chai-Onn was a corporate lawyer at the law firm of Gibson, Dunn & Crutcher LLP, where he performed a variety of corporate, mergers and acquisitions and financial legal work.

Ari Kellen

Dr. Ari Kellen has been appointed as Executive Vice President, Company Group Chairman of the Company., with effective January 1, 2014. Dr. Kellen was a senior partner in McKinsey & Company's Mid-Atlantic Office. Since joining McKinsey in March 1991, Ari has led numerous strategy, organization and performance improvement studies for health care companies, including corporate strategies for boards and top management teams, business unit strategies for medical device, pharmaceutical and biotechnology, and health care services clients, and regional and country growth strategies. In addition, Ari developed business model innovation and turnaround strategies as well as top level organization structure, governance and decision-making redesigns. Ari directed performance turnarounds addressing revenue, cost, capital and change management. Ari received a Bachelor of Medicine and Bachelor of Surgery (MBBCh) degree and an MBA degree, both with distinction, from the University of the Witwatersrand in South Africa.

Laizer Kornwasser

Mr. Laizer D. Kornwasser has been appointed as Executive Vice President, Company Group Chairman of Valeant Pharmaceuticals International Inc., since February 2013He was a Senior Executive at Medco Health prior to its acquisition by Express Scripts. He served as Senior Vice President, Consumer Solutions and Retail Markets and was responsible for retail network and mail pharmacy products and strategy. He oversaw network pricing, negotiations, plan designs and programs that maximized the retail and mail channels. He joined Medco in August 2003, and was initially responsible for building a business development team, post spin-off from Merck. In this role he oversaw all acquisitions and joint ventures and was actively involved in developing the company’s long-term growth strategy. He later assumed responsibility for the companies’ channel and generic drug strategy and was President of its diabetes division, which focused on direct to consumer solutions. Prior to joining Medco, Mr. Kornwasser held positions at Merrill Lynch and Coopers & Lybrand, and served as an associate professor at Yeshiva University.

Brian Stolz

Mr. Brian M. Stolz is Executive Vice President - Administration, Chief Human Capital Officer of Valeant Pharmaceuticals International, Inc., since June 2011. Prior to joining the Company, from February 2009 through June 2011, Mr. Stolz was a Principal at ghSMART, a leadership consulting and advisory firm where he worked with corporate and alternative investment clients on human resource issues. In this role, he assessed and trained C-Level executives and professionals, created and implemented hiring and performance evaluation processes and advised boards and investment committees on senior-level hires. Prior to joining ghSMART, from September 2004 to February 2009, Mr. Stolz was a consultant at McKinsey and was a member of the McKinsey Pharmaceuticals and Medical Products group.

Robert Ingram

Mr. Robert A. Ingram is Lead Independent Director of Valeant Pharmaceuticals International Inc. Mr. Ingram has been serving on the Board of the Company since September 2010, was the Lead Director from September 2010 to December 2010, was the Chairman of the Board from December 2010 to March 2011 and is now the Lead Independent Director. Since January 2007, Mr. Ingram has been a general partner at Hatteras Venture Partners, a venture capital firm with a focus on biopharmaceuticals, medical devices, diagnostics and related opportunities in human medicine. Since January 2010, he has served as a special advisor to the Chief Executive Officer (“CEO”) of GlaxoSmithKline (“GSK”). He served as Vice Chairman Pharmaceuticals of GSK from 2002 through 2009 and Chief Operating Officer and President of Pharmaceutical Operations, CEO of Glaxo Wellcome plc from October 1997 to December 2000 and chairman of the board of Glaxo Wellcome Inc., Glaxo Wellcome plc’s U.S. subsidiary, from January 1999 to December 2000. Mr. Ingram was President and CEO of Glaxo Wellcome Inc. from October 1997 to January 1999. Mr. Ingram is also a member of the Board of Advisors for the H. Lee Moffitt Cancer Center and Research Triangle Institute, as well as Chairman of the Board, Research Triangle Foundation of North Carolina and Glaxo North Carolina Foundation. Mr. Ingram currently serves on the boards of Regeneron Pharmaceuticals, Inc. (member of Compensation Committee), Edwards Life Sciences Corporation (member of compensation committee) and CREE, Inc. (lead director, member of compensation committee and governance and nominations committee). He is a former chairman of the board of Elan Corporation, plc and a former director of Allergan Inc., Misys plc, Nortel Networks Corporation (“Nortel”), Wachovia Corporation, OSI Pharmaceuticals, Inc., Lowe’s Companies, Pharmaceuticals Product Development Inc., and from 2003 served as a director of Valeant Pharmaceuticals International (“VPI”), which was merged into the Company, then known as Biovail Corporation

Ronald Farmer

Mr. Ronald Harold Farmer is an Independent Director of Valeant Pharmaceuticals International, Inc., since August 2011. Since 2003, Mr. Farmer has been the Managing Director of Mosaic Capital Partners, a Toronto-based holding company with interests in several private companies in Canada and the United States. Mr. Farmer is also Director Emeritus of McKinsey & Company (“McKinsey”) where he spent 25 years in the Toronto and New York offices prior to his retirement in 2003. At McKinsey, he worked with leading global corporations in a variety of industries on strategy and organization challenges and held a number of leadership positions, including serving as a Managing Partner of the Canadian practice from 1991 to 1997 and co-leading its Global eBusiness practice. He served on McKinsey’s Shareholder Council (board of directors). Mr. Farmer is a director on several private company boards including Integran Technologies and PowerMetal Technologies. He has also been a director of the Bank of Montreal since 2003 where he serves on the audit, nominating and governance, and human resources committees. He also serves on the Advisory Council of the Schulich School of Business. He is a former director of Afexa Life Sciences Inc.

Colleen Goggins

Ms. Colleen A. Goggins is an Independent Director of Valeant Pharmaceuticals International, Inc. She has been a member of the board of directors of the TD Bank Group since 2012. She is also a member of TD board’s risk committee. In 2013, she joined the Munich-based supervisory board of KraussMaffei Group, a global supplier of machinery and systems for processing plastics and rubber. KraussMaffei Group is a portfolio company of the private equity firm ONEX. Ms. Goggins was employed from 1981 to 2011 by Johnson & Johnson. From 2001 to 2011, she served on Johnson & Johnson’s Executive Committee and as Worldwide Chairman of the Consumer Group, providing strategic leadership for a fully-integrated personal and healthcare portfolio which included many leading brands. Ms. Goggins is involved with a number of non-profit organizations, including University of Wisconsin Foundation (member of the Executive Committee and chair of the Budget and Compensation Committee), University’s Center for Brand and Product Management (member) and New York City Meals-on-Wheels (board member).

Anders Lonner

Mr. Anders Lonner is an Independent Director of Valeant Pharmaceuticals International Inc. Mr. Lönner was the Group President and Chief Executive Officer of Meda AB from November 1999 to October 2013. He was a member of the board at Meda AB from 2000 to October 2013 and served on the board of VPI from January 2009 to September 2010 (member of Compensation Committee from May 2009 to September 2010). Prior to joining Meda AB, Mr. Lönner served as the Vice President Nordic region of Astra and as the Chief Executive officer of Karo Bio. Mr. Lönner currently serves on the board of Karo Bio AB (chairman of the board).

Theo Melas-Kyriazi

Mr. Theo Melas-Kyriazi is an Independent Director of Valeant Pharmaceuticals International Inc., since September 2010. He has been the Chief Financial Officer of Levitronix Technologies LLC, a worldwide leader in magnetically levitated bearingless motor technology, since 2011, and served as the Chief Financial Officer of its affiliate, Levitronix LLC since 2006. He was the Chief Financial Officer of Thermo Electron Corporation from January 1999 through October 2004. Mr. Melas-Kyriazi was a Vice President of Thermo Electron Corporation during 1998, in charge of corporate strategy; he served as the CEO of Thermo Spectra Corporation, a publicly-traded majority-owned subsidiary of Thermo Electron, from 1994 to 1998, and was Treasurer of Thermo Electron Corporation and all of its publicly traded subsidiaries from 1988 to 1994. He is currently a director of Moderna Therapeutics and GeNO LLC. He served on the board of VPI from 2003 until September 2010 and is a former director of Helicos BioSciences Corporation, Cyberkinetics Neurotechnology Systems, Inc. and Glenrose Instruments Inc.

Robert Power

Mr. Robert N. Power is an Independent Director of Valeant Pharmaceuticals International Inc., since August 2008. Mr. Power was a faculty member at The Wharton School of Business, University of Pennsylvania, where he taught multinational marketing from 2009 to 2011. Mr. Power has over 25 years’ experience working in the pharmaceutical and biotechnology industry through a number of leadership positions with Wyeth beginning in 1985 through 2007, including Director — New Product Development, Managing Director — U.K./Ireland, Vice President — Global Marketing, President — Europe, Middle East, Africa, President — International and Executive Vice President — Global Business Operations. Mr. Power also has completed the Director Professionalism course offered by the National Association of Corporate Directors.

Norma Provencio

Ms. Norma A. Provencio is an Independent Director of Valeant Pharmaceuticals International Inc., since September 2010. She has been president and owner of Provencio Advisory Services, Inc., a healthcare financial and operational consulting firm, since October 2003. From May 2002 to September 2003, she was Partner-in-Charge of the Healthcare Industry for the Pacific Southwest for KPMG LLP. From 1979 to May 2002, she was with Arthur Andersen, and was Partner-in-Charge of Arthur Andersen’s Pharmaceutical, Biomedical and Healthcare Practice for the Pacific Southwest from November 1995 to May 2002. Ms. Provencio is currently a member of the Board of Trustees of Loyola Marymount University. Ms. Provencio is currently on the board of Beazer Homes (chair of audit committee and member of compensation committee). Ms. Provencio served on the board of VPI from 2007 until September 2010.

Katharine Stevenson

Ms. Katharine B. Stevenson is an Independent Director of Valeant Pharmaceuticals International Inc., since September 2010. Ms. Stevenson is a Corporate Director who serves on a variety of corporate and not-for-profit boards. She was a senior executive of Nortel from 1995-2007 and has over 20 years of experience as a financial executive in Canada and the United States. Prior to joining Nortel, Ms. Stevenson held various progressively senior finance roles in investment and corporate banking at J.P. Morgan & Company, Inc. She was with J.P. Morgan from 1984 to 1995. Ms. Stevenson is currently a member of the board of directors of CAE Inc. (chair of audit committee), Open Text Corporation (member of audit committee) and Canadian Imperial Bank of Commerce (member of audit committee). She was formerly a director of Afexa Life Sciences, Inc. and a director and audit committee chair of OSI Pharmaceuticals Inc. Ms. Stevenson is a member of the Institute of Corporate Directors with the designation of ICD.D.

Jeffrey Ubben

Mr. Jeffrey W. Ubben is Independent Director of the Company., since October 1, 2014. He is a Founder, Chief Executive Officer and the Chief Investment Officer of ValueAct Capital. Prior to founding ValueAct Capital in 2000, Mr. Ubben was a Managing Partner at Blum Capital Partners for more than five years. Mr. Ubben is a director of Willis Group Holdings plc. He is a former chairman and director of Martha Stewart Living Omnimedia, Inc., and a former director of Acxiom Corp., Catalina Marketing Corp., Gartner Group, Inc., Insurance Auto Auctions, Inc., Mentor Corporation, Omnicare, Inc., Misys, plc, Per-Se Technologies, Inc., Sara Lee Corp. and several other public and private companies. In addition, Mr. Ubben serves as chairman of the national board of the Posse Foundation, is on the board of trustees of Northwestern University, and is also on the board of the American Conservatory Theater.

Laurie Little

Basic Compensation

Search Stocks